FDA Announces Efforts to Implement Real-Time Clinical Trial Reporting.

The FDA's pilot program includes two proof-of-concept clinical trials reporting endpoints and data signals in real time, involving AstraZeneca and Amgen.

• Why it matters: Real-time reporting in clinical trials can improve transparency and accelerate data sharing, addressing gaps in timely information dissemination during drug development.
• What they did: The FDA launched a pilot program with two trials: AstraZeneca's TrAVeRse phase II trial in treatment-naive mantle cell lymphoma and Amgen's planned phase Ib STREAM-SCLC study in limited-stage small cell lung carcinoma.
• The result: This initiative may demonstrate the feasibility of real-time data reporting, potentially transforming clinical trial transparency and efficiency in future drug development processes.